All In Biotech

Drug Trial Radar · NCT04086472

Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)

A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Participants Inoculated With Experimental Respiratory Syncytial Virus

Last checked: Nov 20, 2026Latest source record: Sep 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

80

Actual

Start

Oct 28, 2019

Primary completion

Mar 22, 2020

Study completion Aug 14, 2020

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine if a single intravenous (IV) dose of clesrovimab when administered at 1 of 4 dose levels results in a reduction in viral load after intranasal inoculation (with RSV A Memphis 37b) compared to IV placebo. It is hypothesized that at least 1 of the 4 dose levels of clesrovimab given prior to inoculation will reduce the area under the viral load-time curve (VL-AUC) from Day 2 through Day 11 (inclusive) after viral inoculation (Study Day 31 through Day 40) compared to placebo.

Conditions

  • Respiratory Syncytial Viruses

Interventions

  • ClesrovimabBiological

    Single dose of clesrovimab administered via IV infusion.

  • PlaceboOther

    Placebo (0.9% sodium chloride, USP sterile saline) administered via IV infusion.

  • RSV-A Memphis 37bBiological

    Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Viral Load-time Curve (VL-AUC)Time frame: 10 days; from Day 2 through Day 11 (inclusive) after viral inoculation (Study Day 31 through Day 40)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • HVIVO Services Ltd ( Site 0001)

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.